This bill amends section 28-405 of the Revised Statutes Supplement, 2025, to classify bromazolam as a controlled substance under the Uniform Controlled Substances Act, while also correcting the spelling of certain substances. It introduces a legal definition for bromazolam, specified as "1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one," and replaces the previous name associated with this substance. Additionally, the bill adds "Psilocin" to the list of controlled substances, replacing the term "Psilocyn." The original section of the law will be repealed to accommodate these updates, ensuring that the classification of controlled substances remains accurate and reflective of current scientific understanding.

Moreover, the bill proposes further amendments to drug scheduling laws, introducing new classifications for various synthetic compounds, including tetrahydrocannabinols and naphthoylindoles, while excluding FDA-approved cannabidiol products. It updates the list of substances affecting the central nervous system, adding bromazolam as a depressant and expanding stimulant definitions. The bill also includes new legal language for Schedule II and Schedule III substances, specifying criteria for their classification, and introduces several substances to Schedule IV, such as Dronabinol and Brexanolone. Overall, the bill aims to enhance regulatory oversight of controlled substances, ensuring that substances with potential for abuse are appropriately classified while allowing for necessary medical and veterinary applications.

Statutes affected:
Introduced: 28-405